Shares of CVS Health Corp (NYSE:CVS) have received a consensus rating of “Buy” from the twenty-five ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, twelve have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $85.93.

A number of equities analysts have recently issued reports on the company. SunTrust Banks increased their target price on CVS Health to $90.00 and gave the stock a “buy” rating in a research note on Friday. Morgan Stanley raised CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 target price for the company in a research note on Friday. Vetr downgraded CVS Health from a “buy” rating to a “hold” rating and set a $77.11 target price for the company. in a research note on Thursday. Raymond James Financial raised CVS Health from an “outperform” rating to a “strong-buy” rating and set a $90.00 target price for the company in a research note on Thursday. They noted that the move was a valuation call. Finally, UBS Group raised CVS Health from an “outperform” rating to a “strong-buy” rating in a research note on Thursday.

CVS Health (CVS) traded up $3.32 on Monday, reaching $78.45. The company’s stock had a trading volume of 14,241,000 shares, compared to its average volume of 10,230,000. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. The stock has a market cap of $79,470.00, a P/E ratio of 16.21, a PEG ratio of 1.32 and a beta of 0.90. CVS Health has a 12-month low of $66.45 and a 12-month high of $84.72.

CVS Health (NYSE:CVS) last issued its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.01. The business had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.64 EPS. analysts predict that CVS Health will post 5.9 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, February 2nd. Investors of record on Wednesday, January 24th will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date is Tuesday, January 23rd. CVS Health’s dividend payout ratio is currently 41.32%.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the sale, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.61% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CVS. Pathstone Family Office LLC grew its holdings in CVS Health by 341.0% during the 2nd quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock valued at $2,353,000 after buying an additional 982 shares during the last quarter. Wealthcare Advisory Partners LLC grew its holdings in CVS Health by 330.3% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 991 shares during the last quarter. Fieldpoint Private Securities LLC grew its holdings in CVS Health by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 1,000 shares during the last quarter. Arcadia Investment Management Corp MI grew its holdings in CVS Health by 119.6% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after buying an additional 726 shares during the last quarter. Finally, MPS Loria Financial Planners LLC acquired a new stake in CVS Health during the 2nd quarter valued at $119,000. Institutional investors and hedge funds own 81.63% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “CVS Health Corp (CVS) Given Average Recommendation of “Buy” by Brokerages” was published by Marea Informative and is the property of of Marea Informative. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.mareainformativa.com/2018/01/29/cvs-health-corp-cvs-given-average-recommendation-of-buy-by-brokerages-updated-updated-updated.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.